CereVasc raised $85 million to advance its minimally invasive eShunt system targeting hydrocephalus without traditional brain shunt surgery. The company said it is preparing to complete a pivotal trial and submit to the FDA in 2027, framing the funding around execution of the regulatory pathway. Separately, Cellares and TScan started evaluating automated manufacturing of TSC-101 for AML and MDS patients at risk of relapse after allo-HCT. The collaboration focuses on scalable and consistent production using Cellares’ Cell Shuttle platform and automated quality-release tooling to reduce process variability. Together, the moves show how both med-tech and cell therapy companies are funding scale-up and regulatory-readiness projects to improve access and reduce operational bottlenecks.